Baxalta Declares Quarterly Dividend

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on April 1, 2016, to stockholders of record as of the close of business on March 10, 2016.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.

Forward-Looking Statements

This release includes forward-looking statements concerning Baxalta’s dividend. Such statements are made of the date that they were first issued and are based on current expectations, beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Baxalta's control and which could cause actual results to differ materially from those in the forward-looking statements, including the following: continued strength in the company’s financial position, including cash flows; future decisions of the board of directors of the company with respect to the payment of dividends relative to alternative uses of funds; and other risks identified in Baxalta's filings with the Securities and Exchange Commission, all of which are available on Baxalta's website. Baxalta expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160223007008/en/

Baxalta Media Relations
Geoffrey Mogilner, +1-224-940-8619
[email protected]
or
Baxalta Investor Relations
Mary Kay Ladone, +1-224-940-3371
[email protected]
or
Lorna Williams, +1-224-940-3511
[email protected]

Source: Baxalta Incorporated

You May Also Be Interested In

• Delek US prices $400M in convertible notes due 2031
• IM Cannabis closes $1.31M share offering, citing financial hardship
• Bullish and Equiniti form coalition for tokenized securities standards